In follow-up work, they tested the expression levels of H3K27me3, 5hmC, NSD2, MOF, JARID1B, EZH2, and Ki67 from the same BCC patients that they examined in the previous study, as well as matched non-malignant normal epidermal tissue to further explore the relationship of epigenetic modifiers to BCC. This evidence concerns the gene NSD2 and skin basal cell carcinoma.